Zentalis Pharmaceuticals (ZNTL) Interest & Investment Income (2019 - 2026)

Zentalis Pharmaceuticals' Interest & Investment Income history runs 8 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 198.76% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $21.5 million (up 277.43% YoY), while the FY2025 annual figure was $16.2 million, down 36.52% from the prior year.
• Interest & Investment Income was $2.6 million for Q1 2026 at Zentalis Pharmaceuticals, roughly flat from $2.6 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $34.9 million in Q1 2024 to a low of -$22.9 million in Q2 2024.
• Historically, Interest & Investment Income has averaged $4.3 million across 5 years, with a median of $3.2 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Interest & Investment Income soared 3572.73% in 2022, then slumped 613.66% in 2024.
• A 5-year view of Interest & Investment Income shows it stood at $3.2 million in 2022, then surged by 111.88% to $6.8 million in 2023, then sank by 68.28% to $2.2 million in 2024, then rose by 20.58% to $2.6 million in 2025, then climbed by 0.15% to $2.6 million in 2026.
• The last three Interest & Investment Income figures came in at $2.6 million (Q1 2026), $2.6 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.